Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy
regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of
recurrent small-cell lung cancer.